In addition to the confirmed hypothesized mechanism of Mcl-1 downregulation by CDK9 inhibition synergizing with Bcl-2 inhibition in AML, we found previously unrecognized novel mechanisms that will add to preclinical development as well as guide the use of CDK9 inhibitors in the clinic. The gene discussed is MCL1; the disease is acute myeloid leukemia.